Antitumor agent including low-dose irinotecan hydrochloride hydrate

Antitumor agent including low-dose irinotecan hydrochloride hydrate

Provided is a combination therapy which provides i) the combination of trifluridine (trifluorothymidine / TFT / FTD) and tipiracil hydrochloride (thymidine phosphorylase inhibitor / TPI); in combination with ii) irinotecan hydrochloride hydrate (CPT-11). The combination therapy is characterised in t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Okabe, Hiroyuki
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
DERIVATIVES THEREOF
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SUGARS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Provided is a combination therapy which provides i) the combination of trifluridine (trifluorothymidine / TFT / FTD) and tipiracil hydrochloride (thymidine phosphorylase inhibitor / TPI); in combination with ii) irinotecan hydrochloride hydrate (CPT-11). The combination therapy is characterised in that the FTD/TPI combination drug is provided for administration at a reduced does amount of trifluridine (in the range of 35 to 70 mg/m2/day) combined with CPT-11 provided for administration at a dose in the range of 45 to 144 mg/m2/day.